The Cutaneous Connection: Highlighting Voices of Patients With Indolent Systemic Mastocytosis

Welcome back to the Cutaneous Connection!

In the latest installment of Dermatology Times' video series, Derm Dispatch, host Renata Block, DMSc, MMS, PA-C, speaks with indolent systemic mastocytosis patient advocate Suki Tipp about the prolonged diagnostic journey that reshaped her life—and the pivotal role dermatology clinicians can play in identifying this rare mast cell disorder earlier.

Tipp’s initial presentation began in 2015 with intensely pruritic, hive-like lesions on her legs that evolved into persistent brown macules. Initially attributed to folliculitis with postinflammatory hyperpigmentation, her cutaneous findings were evaluated in isolation from systemic symptoms, including flushing, severe gastrointestinal pain, diarrhea, headaches, and mood changes. The episodic and seemingly unrelated nature of her manifestations complicated pattern recognition across specialties.

Her condition escalated following a life-threatening anaphylactic reaction to a wasp sting that required critical care admission. Although systemic mastocytosis was eventually suspected, fragmented subspecialty care delayed confirmation. A requested skin biopsy was deferred, and no single clinician integrated her dermatologic, allergic, gastrointestinal, and neuropsychiatric symptoms into a unifying diagnosis. At her most severe, Tipp required 99 epinephrine auto-injectors in one year due to recurrent anaphylaxis and became unable to work, subsisting on a highly restricted diet.

The episode also explores the psychological burden of rare disease, stigma surrounding mast cell–associated neuropsychiatric symptoms, and the financial toxicity of high-dose antihistamines, mast cell stabilizers, and supportive therapies. Tipp underscores the importance of proactive conversations about medication affordability and adherence barriers.

Ultimately, enrollment in a clinical trial of avapritinib (Ayvakit; Blueprint Medicines) at the University of Alabama at Birmingham led to substantial improvement in both systemic symptoms and cutaneous lesions within months.

Tipp now advocates for heightened clinical suspicion when patients present with recurrent urticaria, flushing, unexplained brown macules, and multisystem complaints. She calls on clinicians to embrace multidisciplinary collaboration, acknowledge uncertainty when appropriate, and pursue comprehensive evaluation rather than compartmentalized symptom management.

Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at [email protected].